Pharma Deals Review, Vol 2003, No 36 (2003)

Font Size:  Small  Medium  Large

Eyetech Pharmaceuticals Enters Deal to Market Pfizer’s Xalatan®

Business Review Editor

Abstract


Eyetech entered into a deal to market Pfizer’s Xalatan® (for treating glaucoma) in US. The financial terms of the agreement were not disclosed.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.